ProPhase Labs is actively seeking a sale or strategic partnership for its BE‑Smart esophageal cancer risk‑stratification test, a CLIA‑certified, CAP‑accredited laboratory‑developed test that has been validated in a Mayo Clinic pilot study and published in the *Journal of Clinical Gastroenterology and Hepatology*. The company has reached out to more than 70 potential acquirers and partners, targeting firms that can accelerate commercialization and bring the test to the approximately 7 million upper‑endoscopies performed annually in the United States for GERD and Barrett’s surveillance, a market that could generate up to $14 billion in annual revenue.
Continue reading for full analysis...